Mcl clinical trials

Explore recruiting mcl clinical trials.

Recruiting mcl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK‑2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (waveLINE-006).

Spain, Czechia, Portugal, Sweden, Poland, Estonia +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

TRIANGLE - autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial

Norway, Spain, Poland, Czechia, Sweden, Belgium +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Poland, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)

Portugal, Belgium, Czechia, Austria, Denmark, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Mcl trials by city

Mcl in Toronto Mcl in Vancouver Mcl in Montreal Mcl in Calgary Mcl in Edmonton Mcl in Ottawa Mcl in Winnipeg Mcl in Quebec City Mcl in Hamilton Mcl in Kitchener Mcl in London Mcl in Halifax Mcl in New York Mcl in Los Angeles Mcl in Chicago Mcl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease